glp 1 drugs pregnancy Discontinuing GLP-1s Before or Early in Tied to Weight Gain, Pregnancy Complications How GLP-1 Drugs Can Affect

In the U.S., about 6% of adults currently use GLP-1s, and 12% have used them in the past (2024 data) (Mozafariun 2025)

A study has analyzed how plasma DPP-4 activity and levels of soluble DPP-4 correlate with inflammatory markers (C-reactive protein [CRP], IL-6, TNF-, and monocyte chemoattractant protein-1 [MCP-1]) in a subset of patients with T2DM treated with sitagliptin for 12 months as part of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS, 26)

Ndumele, C.E., et al., A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

As a result, a full risk-of-bias assessment could not be performed

India is emerging in the GLP-1 targeted peptide weight loss drugs market due to its large and growing population affected by obesity and diabetes, creating a substantial patient base

GLP-1 is quickly degraded by the dipeptidyl peptidase 4 (DPP-4) enzyme, making the plasma half-life 1-2 minutes